From Name:
From Email:
To Name:
To Email:

Optional Message:

Dezima Extends Clinical Development of Dyslipidemia Drug

from Drug Discovery & Development

Dezima Pharma, the biotechnology company developing innovative drugs in the field of dyslipidemia, announced the approval of a Phase 1 pilot study in subjects with isolated, elevated Lipoprotein(a) (Lp(a)), for which additional funding has been secured. The aim of this new study is to investigate the Lp(a) lowering effects of TA-8995 (DEZ-001), a best-in-class CETP inhibitor, in 36 asymptomatic subjects with isolated, elevated Lp(a) levels. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063